{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:40:52Z","timestamp":1788907252505,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["MOST 111-2811-B-197-001"],"award-info":[{"award-number":["MOST 111-2811-B-197-001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["MOST 111-2628-B-197-001-MY3"],"award-info":[{"award-number":["MOST 111-2628-B-197-001-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-D-111048"],"award-info":[{"award-number":["TSGH-D-111048"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-C01-110015"],"award-info":[{"award-number":["TSGH-C01-110015"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-C01-110016"],"award-info":[{"award-number":["TSGH-C01-110016"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013179","name":"Teh-Tzer Study Group for Human Medical Research Foundation of Taiwan","doi-asserted-by":"publisher","award":["B1101034"],"award-info":[{"award-number":["B1101034"]}],"id":[{"id":"10.13039\/501100013179","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s10753-023-01939-7","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T15:03:15Z","timestamp":1707231795000},"page":"696-717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Angiotensin II Receptor Neprilysin Inhibitor LCZ696 Inhibits the NLRP3 Inflammasome By Reducing Mitochondrial Dysfunction in Macrophages and Alleviates Dextran Sulfate Sodium-induced Colitis in a Mouse Model"],"prefix":"10.1007","volume":"47","author":[{"given":"Hsiao-Wen","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hsien","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Che","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Ta","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Lung","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Meng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Chung","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Feng","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"issue":"4","key":"1939_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","volume":"50","author":"J Gu","year":"2010","unstructured":"Gu, J., A. Noe, P. Chandra, S. Al-Fayoumi, M. Ligueros-Saylan, R. Sarangapani, S. Maahs, G. Ksander, D.F. Rigel, A.Y. Jeng, T.H. Lin, W. Zheng, and W.P. Dole. 2010. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).\u00a0Journal\u00a0of\u00a0Clinical Pharmacology\u00a050 (4): 401\u2013414. https:\/\/doi.org\/10.1177\/0091270009343932.","journal-title":"J Clin Pharmacol"},{"key":"1939_CR2","doi-asserted-by":"publisher","unstructured":"Ruilope, L.M., A. Dukat, M. B\u00f6hm, Y. Lacourci\u00e8re. J. Gong, and M.P. Lefkowitz. 2010.\u00a0Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375 (9722): 1255\u20131266. https:\/\/doi.org\/10.1016\/S0140-6736(09)61966-8.","DOI":"10.1016\/S0140-6736(09)61966-8"},{"issue":"11","key":"1939_CR3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray, J.J., M. Packer, A.S. Desai, J. Gong, M.P. Lefkowitz, A.R. Rizkala, J.L. Rouleau, V.C. Shi, S.D. Solomon, K. Swedberg, PARADIGM-HF Investigators and Committees. 2014. Angiotensin-neprilysin inhibition versus enalapril in heart failure.\u00a0The\u00a0New England Journal of Medicine\u00a0371 (11): 993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077.","journal-title":"N Engl J Med"},{"key":"1939_CR4","doi-asserted-by":"publisher","unstructured":"Solomon, S.D.,\u00a0M. Zile,  B. Pieske,  A. Voors,  A. Shah,  E. Kraigher-Krainer,  V. Shi,  T. Bransford,  M. Takeuchi,  J. Gong,  M. Lefkowitz,  M. Packer, and  J.J. McMurray. 2012. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 80 (9851): 1387\u20131395. https:\/\/doi.org\/10.1016\/S0140-6736(12)61227-6.","DOI":"10.1016\/S0140-6736(12)61227-6"},{"key":"1939_CR5","doi-asserted-by":"publisher","unstructured":"Zhang, R., X. Sun, Y. Li,  W. He,  H. Zhu, B. Liu, and A. Zhang. 2022. The efficacy and safety of Sacubitril\/Valsartan in heart failure patients: A Review.\u00a0Journal\u00a0of\u00a0Cardiovascular Pharmacology\u00a0Therapeutics 27: 10742484211058681. https:\/\/doi.org\/10.1177\/10742484211058681.","DOI":"10.1177\/10742484211058681"},{"issue":"5","key":"1939_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrcardio.2017.44","volume":"14","author":"I Fern\u00e1ndez-Ruiz","year":"2017","unstructured":"Fern\u00e1ndez-Ruiz, I. 2017. Diabetes: Sacubitril\/Valsartan improves glycaemic control.\u00a0Nature Reviews Cardiology\u00a014 (5): 252. https:\/\/doi.org\/10.1038\/nrcardio.2017.44.","journal-title":"Nat Rev Cardiol"},{"issue":"15","key":"1939_CR7","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","volume":"138","author":"R Haynes","year":"2018","unstructured":"Haynes, R., P.K. Judge, N. Staplin, W.G. Herrington, B.C. Storey, A. Bethel, L. Bowman, N. Brunskill, P. Cockwell, M. Hill, P.A. Kalra, J.J.V. McMurray, M. Taal, D.C. Wheeler, M.J. Landray, and C. Baigent. 2018. Effects of Sacubitril\/Valsartan versus Irbesartan in patients with chronic kidney disease. Circulation 138 (15): 1505\u20131514. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034818.","journal-title":"Circulation"},{"issue":"3","key":"1939_CR8","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.3390\/ijms23031288","volume":"23","author":"OM Belali","year":"2022","unstructured":"Belali, O.M., M.M. Ahmed, M. Mohany, T.M. Belali, M.M. Alotaibi, A. Al-Hoshani, and S.S. Al-Rejaie. 2022. LCZ696 protects against diabetic cardiomyopathy-induced myocardial inflammation, ER stress, and apoptosis through inhibiting AGEs\/NF-\u03baB and PERK\/CHOP signaling pathways.\u00a0International Journal of Molecular Sciences\u00a023 (3): 1288. https:\/\/doi.org\/10.3390\/ijms23031288.","journal-title":"Int J Mol Sci"},{"key":"1939_CR9","doi-asserted-by":"publisher","unstructured":"Ye, S.,\u00a0L. Su, P. Shan,  B. Ye, S. Wu,  G. Liang, and\u00a0 W. Huang. 2021. LCZ696 attenuated doxorubicin-induced chronic cardiomyopathy through the TLR2-MyD88 complex formation.\u00a0Frontiers in\u00a0Cell\u00a0and\u00a0Developmental Biology\u00a09: 654051. https:\/\/doi.org\/10.3389\/fcell.2021.654051.","DOI":"10.3389\/fcell.2021.654051"},{"key":"1939_CR10","doi-asserted-by":"publisher","unstructured":"Alqahtani, F., M. Mohany, A.F. Alasmari, A.Z. Alanazi, O.M. Belali, M.M. Ahmed, and S.S. Al-Rejaie. 2020.\u00a0Angiotensin II receptor neprilysin inhibitor (LCZ696) compared to Valsartan attenuates hepatotoxicity in STZ-induced hyperglycemic rats.\u00a0International Journal\u00a0of Medicine and\u00a0Medical Sciences\u00a017 (18): 3098\u20133106. https:\/\/doi.org\/10.7150\/ijms.49373.","DOI":"10.7150\/ijms.49373"},{"key":"1939_CR11","doi-asserted-by":"publisher","unstructured":"Acanfora, D., M. Ciccone, P. Scicchitano, C. Acanfora, and G. Casucci. 2020.\u00a0Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril\/valsartan): rationale for adoption in SARS-CoV-2 patients.\u00a0The\u00a0European Heart Journal\u00a0-\u00a0Cardiovascular Pharmacotherapy\u00a06 (3): 135\u2013136. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa028.","DOI":"10.1093\/ehjcvp\/pvaa028"},{"key":"1939_CR12","doi-asserted-by":"publisher","unstructured":"Vitiello A.,\u00a0R. La Porta, and  F. Ferrara. 2021. Scientific hypothesis and rational pharmacological for the use of sacubitril\/valsartan in cardiac damage caused by COVID-19.\u00a0Medical\u00a0Hypotheses\u00a0147: 110486. https:\/\/doi.org\/10.1016\/j.mehy.2021.110486.","DOI":"10.1016\/j.mehy.2021.110486"},{"issue":"3","key":"1939_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/JLB.3MR0520-104RR","volume":"109","author":"J Moretti","year":"2021","unstructured":"Moretti, J., and J.M. Blander. 2021. Increasing complexity of NLRP3 inflammasome regulation.\u00a0Journal\u00a0of\u00a0Leukocyte Biology\u00a0109 (3): 561\u2013571. https:\/\/doi.org\/10.1002\/JLB.3MR0520-104RR.","journal-title":"J Leukoc Biol"},{"key":"1939_CR14","doi-asserted-by":"publisher","first-page":"111442","DOI":"10.1016\/j.biopha.2021.111442","volume":"138","author":"QL Chen","year":"2021","unstructured":"Chen, Q.L., H.R. Yin, Q.Y. He, and Y. Wang. 2021. Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease. Biomed Pharmacother 138: 111442. https:\/\/doi.org\/10.1016\/j.biopha.2021.111442.","journal-title":"Biomed Pharmacother"},{"key":"1939_CR15","doi-asserted-by":"publisher","unstructured":"Takahashi, M. 2022. NLRP3 inflammasome as a key driver of vascular disease.\u00a0Cardiovascular Research\u00a0118 (2): 372\u2013385. https:\/\/doi.org\/10.1093\/cvr\/cvab010.","DOI":"10.1093\/cvr\/cvab010"},{"issue":"12","key":"1939_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3390\/biom9120850","volume":"9","author":"S Ding","year":"2019","unstructured":"Ding, S., S. Xu, Y. Ma, G. Liu, H. Jang, and J. Fang. 2019. Modulatory Mechanisms of the NLRP3 Inflammasomes in Diabetes. Biomolecules 9 (12): 850. https:\/\/doi.org\/10.3390\/biom9120850.","journal-title":"Biomolecules"},{"issue":"8","key":"1939_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41581-019-0158-z","volume":"15","author":"T Komada","year":"2019","unstructured":"Komada, T., and D.A. Muruve. 2019. The role of inflammasomes in kidney disease.\u00a0Nature Reviews Nephrology\u00a015 (8): 501\u2013520. https:\/\/doi.org\/10.1038\/s41581-019-0158-z.","journal-title":"Nat Rev Nephrol"},{"key":"1939_CR18","doi-asserted-by":"publisher","unstructured":"Szekanecz, Z.,\u00a0S. Szamosi,  G.E. Kov\u00e1cs,  E. Kocsis, and  S. Benk\u0151. 2019. The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout.\u00a0Archives of Biochemistry and Biophysics\u00a0670: 82\u201393. https:\/\/doi.org\/10.1016\/j.abb.2019.01.031.","DOI":"10.1016\/j.abb.2019.01.031"},{"key":"1939_CR19","doi-asserted-by":"publisher","unstructured":"Sharma, B.R., and T.D. Kanneganti.\u00a0NLRP3 inflammasome in cancer and metabolic diseases.\u00a0Nature Immunology\u00a022 (5): 550\u2013559. https:\/\/doi.org\/10.1038\/s41590-021-00886-5.","DOI":"10.1038\/s41590-021-00886-5"},{"key":"1939_CR20","doi-asserted-by":"publisher","unstructured":"Potere, N., M.G. Del Buono, R. Caricchio, P.C. Cremer, A. Vecchi\u00e9, E. Porreca, D. Dalla Gasperina, F. Dentali, A. Abbate, and A. Bonaventura. 2022.\u00a0Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications. EBioMedicine 85: 104299. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104299.","DOI":"10.1016\/j.ebiom.2022.104299"},{"key":"1939_CR21","doi-asserted-by":"publisher","unstructured":"Zhang, X.,  A. Xu,  J. Lv,  Q. Zhang,  Y. Ran,  C. Wei, and  J. Wu. 2020. Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases.\u00a0European Journal of Medicinal Chemistry\u00a0185: 111822. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111822.","DOI":"10.1016\/j.ejmech.2019.111822"},{"key":"1939_CR22","doi-asserted-by":"publisher","unstructured":"Zahid, A., B. Li,  AJK. Kombe,  T. Jin, and  J. Tao. 2019. Pharmacological Inhibitors of the NLRP3 Inflammasome.\u00a0Frontiers in\u00a0Immunology\u00a0https:\/\/doi.org\/10.3389\/fimmu.2019.02538.","DOI":"10.3389\/fimmu.2019.02538"},{"key":"1939_CR23","doi-asserted-by":"publisher","first-page":"870627","DOI":"10.3389\/fimmu.2022.870627","volume":"13","author":"WY Lin","year":"2022","unstructured":"Lin, W.Y., L.H. Li, Y.Y. Hsiao, W.T. Wong, H.W. Chiu, H.T. Hsu, Y.J. Peng, C.L. Ho, O.V. Chernikov, S.M. Cheng, S.P. Yang, and K.F. Hua. 2022. Repositioning of the angiotensin II receptor antagonist Candesartan as an anti-inflammatory agent with NLRP3 inflammasome inhibitory activity.\u00a0Frontiers in\u00a0Immunology\u00a013: 870627. https:\/\/doi.org\/10.3389\/fimmu.2022.870627.","journal-title":"Front Immunol"},{"key":"1939_CR24","doi-asserted-by":"publisher","unstructured":"Wong, W.T., L.H. Li, Y.K. Rao, S.P. Yang, S.M. Cheng, W.Y. Lin, C.C. Cheng, A. Chen, and K.F. Hua. 2018.\u00a0Repositioning of the \u03b2-blocker Carvedilol as a novel autophagy inducer that inhibits the NLRP3 inflammasome.\u00a0Frontiers in\u00a0Immunology\u00a09: 1920. https:\/\/doi.org\/10.3389\/fimmu.2018.01920.","DOI":"10.3389\/fimmu.2018.01920"},{"issue":"5","key":"1939_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10557-020-06995-x","volume":"34","author":"X Li","year":"2020","unstructured":"Li, X., Q. Zhu, Q. Wang, Q. Zhang, Y. Zheng, L. Wang, and Q. Jin. 2020. Protection of Sacubitril\/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.\u00a0Cardiovascular Drugs\u00a0and\u00a0Therapy\u00a034 (5): 629\u2013640. https:\/\/doi.org\/10.1007\/s10557-020-06995-x.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1939_CR26","doi-asserted-by":"publisher","unstructured":"Shen, J.,\u00a0Z. Fan, G. Sun, and  G. Qi. 2021. Sacubitril\/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3\u2011induced pyroptosis via the TAK1\/JNK signaling pathway.\u00a0Molecular Medicine Reports\u00a024 (3): 676. https:\/\/doi.org\/10.3892\/mmr.2021.12315.","DOI":"10.3892\/mmr.2021.12315"},{"issue":"1","key":"1939_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00011-012-0555-2","volume":"62","author":"PC Liao","year":"2013","unstructured":"Liao, P.C., L.K. Chao, J.C. Chou, W.C. Dong, C.N. Lin, C.Y. Lin, A. Chen, S.M. Ka, C.L. Ho, and K.F. Hua. 2013. Lipopolysaccharide\/adenosine triphosphate-mediated signal transduction in the regulation of NLRP3 protein expression and caspase-1-mediated interleukin-1\u03b2 secretion.\u00a0Inflammation Research\u00a062 (1): 89\u201396. https:\/\/doi.org\/10.1007\/s00011-012-0555-2.","journal-title":"Inflamm Res"},{"key":"1939_CR28","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3389\/fimmu.2019.01815","volume":"10","author":"LH Li","year":"2019","unstructured":"Li, L.H., J.S. Lin, H.W. Chiu, W.Y. Lin, T.C. Ju, F.H. Chen, O.V. Chernikov, M.L. Liu, J.C. Chang, C.H. Hsu, A. Chen, S.M. Ka, H.W. Gao, and K.F. Hua. 2019. Mechanistic Insight Into the Activation of the NLRP3 Inflammasome by Neisseria gonorrhoeae in Macrophages.\u00a0Frontiers in\u00a0Immunology\u00a010: 1815. https:\/\/doi.org\/10.3389\/fimmu.2019.01815.","journal-title":"Front Immunol"},{"key":"1939_CR29","doi-asserted-by":"publisher","unstructured":"Tsai W.C.,\u00a0WT. Wong, H.T. Hsu, Y.H. Cheng, Y.H. Yu, W.J. Chen, C.L. Ho, H.C. Hsu, K.F. Hua. 2022. Surfactin Containing Bacillus licheniformis-Fermented Products Alleviate Dextran Sulfate Sodium-Induced Colitis by Inhibiting Colonic Inflammation and the NLRP3 Inflammasome in Mice. Animals (Basel) 12 (24): 3456. https:\/\/doi.org\/10.3390\/ani12243456.","DOI":"10.3390\/ani12243456"},{"key":"1939_CR30","doi-asserted-by":"publisher","unstructured":"Yang, N.,\u00a0Z. Xia,  N. Shao,  B. Li,  L. Xue,  Y. Peng, F. Zhi, and Y. Yang. 2017. Carnosic acid prevents dextran sulfate sodium-induced acute colitis associated with the regulation of the Keap1\/Nrf2 pathway.\u00a0Scientific Reports\u00a07 (1): 11036. https:\/\/doi.org\/10.1038\/s41598-017-11408-5.","DOI":"10.1038\/s41598-017-11408-5"},{"key":"1939_CR31","doi-asserted-by":"publisher","first-page":"991044","DOI":"10.3389\/fimmu.2022.991044","volume":"13","author":"Y Pan","year":"2022","unstructured":"Pan, Y., W. Cai, J. Huang, A. Cheng, M. Wang, Z. Yin, and R. Jia. 2022. Pyroptosis in development, inflammation and disease. Frontiers in Immunology 13: 991044. https:\/\/doi.org\/10.3389\/fimmu.2022.991044.","journal-title":"Frontiers in Immunology"},{"key":"1939_CR32","doi-asserted-by":"publisher","unstructured":"Qiu, Y.,\u00a0Y. Huang,  M. Chen,  Y. Yang,  X. Li, and W. Zhang. 2022. Mitochondrial DNA in NLRP3 inflammasome activation.\u00a0International Immunopharmacology\u00a0108: 108719. https:\/\/doi.org\/10.1016\/j.intimp.2022.108719.","DOI":"10.1016\/j.intimp.2022.108719"},{"key":"1939_CR33","doi-asserted-by":"publisher","first-page":"591803","DOI":"10.3389\/fimmu.2020.591803","volume":"11","author":"M Biasizzo","year":"2020","unstructured":"Biasizzo, M., and N. Kopitar-Jerala. 2020. Interplay Between NLRP3 Inflammasome and Autophagy.\u00a0Frontiers in\u00a0Immunology\u00a011: 591803. https:\/\/doi.org\/10.3389\/fimmu.2020.591803.","journal-title":"Front Immunol"},{"key":"1939_CR34","doi-asserted-by":"publisher","unstructured":"Tao, Y.,\u00a0N. Wang,  T. Qiu, and  X. Sun. 2020. The Role of Autophagy and NLRP3 Inflammasome in Liver Fibrosis.\u00a0BioMed Research International\u00a07269150. https:\/\/doi.org\/10.1155\/2020\/7269150.","DOI":"10.1155\/2020\/7269150"},{"issue":"7575","key":"1939_CR35","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nature15541","volume":"526","author":"N Kayagaki","year":"2015","unstructured":"Kayagaki, N., I.B. Stowe, B.L. Lee, K. O\u2019Rourke, K. Anderson, S. Warming, T. Cuellar, B. Haley, M. Roose-Girma, Q.T. Phung, P.S. Liu, J.R. Lill, H. Li, J. Wu, S. Kummerfeld, J. Zhang, W.P. Lee, S.J. Snipas, G.S. Salvesen, L.X. Morris, L. Fitzgerald, Y. Zhang, E.M. Bertram, C.C. Goodnow, and V.M. Dixit. 2015. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526 (7575): 666\u2013671. https:\/\/doi.org\/10.1038\/nature15541.","journal-title":"Nature"},{"issue":"5","key":"1939_CR36","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1128\/IAI.02895-14","volume":"83","author":"E Gabrielli","year":"2015","unstructured":"Gabrielli, E., E. Pericolini, E. Luciano, S. Sabbatini, E. Roselletti, S. Perito, L. Kasper, B. Hube, and A. Vecchiarelli. 2015. Induction of caspase-11 by aspartyl proteinases of Candida albicans and implication in promoting inflammatory response. Infection and Immunity 83 (5): 1940\u20131948. https:\/\/doi.org\/10.1128\/IAI.02895-14.","journal-title":"Infection and Immunity"},{"issue":"1","key":"1939_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s13105-021-00785-1","volume":"77","author":"Y Wang","year":"2021","unstructured":"Wang, Y., X. Zhang, Y. Guo, X. Li, G. Guo, Z. Niu, and J. Zhang. 2021. Type 1 interferon aggravates lipopolysaccharide-induced sepsis through upregulating Caspase-11 and Gasdermin D. Journal of Physiology and Biochemistry 77 (1): 85\u201392. https:\/\/doi.org\/10.1007\/s13105-021-00785-1.","journal-title":"Journal of Physiology and Biochemistry"},{"issue":"9","key":"1939_CR38","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.apsb.2021.02.006","volume":"11","author":"BE Burdette","year":"2021","unstructured":"Burdette, B.E., A.N. Esparza, H. Zhu, and S. Wang. 2021. Gasdermin D in pyroptosis. Acta Pharm Sin B 11 (9): 2768\u20132782. https:\/\/doi.org\/10.1016\/j.apsb.2021.02.006.","journal-title":"Acta Pharm Sin B"},{"key":"1939_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1146\/annurev-cellbio-021820-101354","volume":"36","author":"AT Moehlman","year":"2020","unstructured":"Moehlman, A.T., and R.J. Youle. 2020. Mitochondrial Quality Control and Restraining Innate Immunity.\u00a0The\u00a0Annual Review\u00a0of\u00a0Cell\u00a0and\u00a0Developmental Biology\u00a036: 265\u2013289. https:\/\/doi.org\/10.1146\/annurev-cellbio-021820-101354.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"1939_CR40","doi-asserted-by":"publisher","unstructured":"Xian, H., K. Watari,  E. Sanchez-Lopez,  J. Offenberger,  J. Onyuru,  H. Sampath,  W. Ying,\u00a0H.M. Hoffman, G.S. Shadel,\u00a0and  M. Karin. 2022. Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling. Immunity 55 (8): 1370\u20131385.e8. https:\/\/doi.org\/10.1016\/j.immuni.2022.06.007.","DOI":"10.1016\/j.immuni.2022.06.007"},{"key":"1939_CR41","doi-asserted-by":"publisher","unstructured":"Zhong, Z., S. Liang,  E. Sanchez-Lopez, F. He, S. Shalapour,\u00a0 XJ. Lin, J. Wong, S. Ding, E. Seki,\u00a0 B. Schnabl, AL. Hevener,  HB. Greenberg, T. Kisseleva, and M. Karin. 2018. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature 560(7717):198\u2013203. https:\/\/doi.org\/10.1038\/s41586-018-0372-z.","DOI":"10.1038\/s41586-018-0372-z"},{"key":"1939_CR42","doi-asserted-by":"publisher","unstructured":"Zhou, R., A.S. Yazdi, P. Menu, and J. Tschopp. 2011. A role for mitochondria in NLRP3 inflammasome activation. Nature 469 (7329): 221\u2013225. https:\/\/doi.org\/10.1038\/nature09663.","DOI":"10.1038\/nature09663"},{"key":"1939_CR43","doi-asserted-by":"publisher","unstructured":"Baroja-Mazo, A., F. Mart\u00edn-S\u00e1nchez, A.I. Gomez, C.M. Mart\u00ednez, J. Amores-Iniesta, V. Compan, M. Barber\u00e0-Cremades, J. Yag\u00fce, E. Ruiz-Ortiz, J. Ant\u00f3n, S. Buj\u00e1n, I. Couillin, D. Brough, J.I. Arostegui, and P. Pelegr\u00edn. 2014.\u00a0The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response.\u00a0Nature Immunology\u00a015 (8): 738\u2013748. https:\/\/doi.org\/10.1038\/ni.2919.","DOI":"10.1038\/ni.2919"},{"key":"1939_CR44","doi-asserted-by":"publisher","unstructured":"Tan, H.W.S.,\u00a0G. Lu,  H. Dong,  Y.L. Cho,  A. Natalia,  L. Wang,  C. Chan,  D. Kappei, S.C. Taneja Ling,  H. Shao,  S.Y. Tsai,  WX. Ding, and  H.M. Shen. 2022. A degradative to secretory autophagy switch mediates mitochondria clearance in the absence of the mATG8-conjugation machinery.\u00a0Nature Communications\u00a013 (1): 3720. https:\/\/doi.org\/10.1038\/s41467-022-31213-7.","DOI":"10.1038\/s41467-022-31213-7"},{"issue":"4","key":"1939_CR45","first-page":"397","volume":"2","author":"A Puissant","year":"2012","unstructured":"Puissant, A., N. Fenouille, and P. Auberger. 2012. When autophagy meets cancer through p62\/SQSTM1. American Journal of Cancer Research 2 (4): 397\u2013413.","journal-title":"American Journal of Cancer Research"},{"key":"1939_CR46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.imlet.2021.10.004","volume":"240","author":"H Tang","year":"2021","unstructured":"Tang, H., X. Tang, Z. Guo, H. Cheng, X. Zheng, G. Chen, H. Huang, W. Wang, J. Gao, Y. Sheng, X. Fan, and L. Sun. 2021. AURKA facilitates the psoriasis-related inflammation by impeding autophagy-mediated AIM2 inflammasome suppression. Immunology Letters 240: 98\u2013105. https:\/\/doi.org\/10.1016\/j.imlet.2021.10.004.","journal-title":"Immunology Letters"},{"key":"1939_CR47","doi-asserted-by":"publisher","unstructured":"Jiang, H., Y. Xie, J. Lu, H. Li, K. Zeng, Z. Hu, D. Wu, J. Yang, Z. Yao, H. Chen, X. Gong, and X. Yu. 2023. Pristimerin suppresses AIM2 inflammasome by modulating AIM2-PYCARD\/ASC stability via selective autophagy to alleviate tendinopathy. Autophagy 1\u201318. https:\/\/doi.org\/10.1080\/15548627.2023.2249392.","DOI":"10.1080\/15548627.2023.2249392"},{"key":"1939_CR48","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.freeradbiomed.2023.08.031","volume":"208","author":"T Hao","year":"2023","unstructured":"Hao, T., W. Fang, D. Xu, Q. Chen, Q. Liu, K. Cui, X. Cao, Y. Li, K. Mai, and Q. Ai. 2023. Phosphatidylethanolamine alleviates OX-LDL-induced macrophage inflammation by upregulating autophagy and inhibiting NLRP1 inflammasome activation. Free Radical Biology & Medicine 208: 402\u2013417. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2023.08.031.","journal-title":"Free Radical Biology & Medicine"},{"issue":"2","key":"1939_CR49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.micinf.2017.10.007","volume":"20","author":"MS Jabir","year":"2018","unstructured":"Jabir, M.S., G.M. Sulaiman, Z.J. Taqi, and D. Li. 2018. Iraqi propolis increases degradation of IL-1\u03b2 and NLRC4 by autophagy following Pseudomonas aeruginosa infection. Microbes and Infection 20 (2): 89\u2013100. https:\/\/doi.org\/10.1016\/j.micinf.2017.10.007.","journal-title":"Microbes and Infection"},{"key":"1939_CR50","doi-asserted-by":"publisher","unstructured":"Gao, A., Y. Wang,  X. Gao, and W. Tian. 2021. LCZ696 ameliorates lipopolysaccharide-induced endothelial injury. Aging (Albany NY) 13 (7): 9582\u2013270. https:\/\/doi.org\/10.18632\/aging.202692.","DOI":"10.18632\/aging.202692"},{"key":"1939_CR51","doi-asserted-by":"publisher","unstructured":"Sho, T.,\u00a0and J. Xu. 2019. Role and mechanism of ROS scavengers in alleviating NLRP3-mediated inflammation.\u00a0Biotechnology\u00a0and\u00a0Applied Biochemistry\u00a066(1):4\u201313. https:\/\/doi.org\/10.1002\/bab.1700.","DOI":"10.1002\/bab.1700"},{"key":"1939_CR52","doi-asserted-by":"publisher","first-page":"6077429","DOI":"10.1155\/2022\/6077429","volume":"2022","author":"M Hou","year":"2022","unstructured":"Hou, M., L. Lu, X. Wu, and H. Liu. 2022. LCZ696 Ameliorates Isoproterenol-Induced Acute Heart Failure in Rats by Activating the Nrf2 Signaling Pathway.\u00a0Applied Bionics\u00a0and\u00a0Biomechanic\u00a02022: 6077429. https:\/\/doi.org\/10.1155\/2022\/6077429.","journal-title":"Appl Bionics Biomech"},{"issue":"3","key":"1939_CR53","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.pop.2023.03.009","volume":"50","author":"LP Bruner","year":"2023","unstructured":"Bruner, L.P., A.M. White, and S. Proksell. 2023. Inflammatory Bowel Disease. Primary Care 50 (3): 411\u2013427. https:\/\/doi.org\/10.1016\/j.pop.2023.03.009.","journal-title":"Prim Care"},{"key":"1939_CR54","doi-asserted-by":"publisher","first-page":"7247238","DOI":"10.1155\/2019\/7247238","volume":"2019","author":"Q Guan","year":"2019","unstructured":"Guan, Q. 2019. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease.\u00a0Journal\u00a0of\u00a0Immunology Research\u00a02019: 7247238. https:\/\/doi.org\/10.1155\/2019\/7247238.","journal-title":"J Immunol Res"},{"key":"1939_CR55","doi-asserted-by":"publisher","unstructured":"Song, Y.,\u00a0Y. Zhao,  Y. Ma,  Z. Wang,  L. Rong,  B. Wang, and  N. Zhang. 2021. Biological functions of NLRP3 inflammasome: A therapeutic target in inflammatory bowel disease.\u00a0Cytokine\u00a0&\u00a0Growth Factor Reviews\u00a060: 61\u201375. https:\/\/doi.org\/10.1016\/j.cytogfr.2021.03.003.","DOI":"10.1016\/j.cytogfr.2021.03.003"},{"key":"1939_CR56","doi-asserted-by":"publisher","first-page":"13727","DOI":"10.1038\/ncomms13727","volume":"7","author":"H Song","year":"2016","unstructured":"Song, H., B. Liu, W. Huai, Z. Yu, W. Wang, J. Zhao, L. Han, G. Jiang, L. Zhang, C. Gao, and W. Zhao. 2016. The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3. Nature Communications 7: 13727. https:\/\/doi.org\/10.1038\/ncomms13727.","journal-title":"Nature Communications"},{"key":"1939_CR57","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jare.2023.08.008","volume":"52","author":"Y An","year":"2023","unstructured":"An, Y., Z. Zhai, X. Wang, Y. Ding, L. He, L. Li, Q. Mo, C. Mu, R. Xie, T. Liu, W. Zhong, B. Wang, and H. Cao. 2023. Targeting Desulfovibrio vulgaris flagellin-induced NAIP\/NLRC4 inflammasome activation in macrophages attenuates ulcerative colitis. Journal of Advanced Research 52: 219\u2013232. https:\/\/doi.org\/10.1016\/j.jare.2023.08.008.","journal-title":"Journal of Advanced Research"},{"issue":"11","key":"1939_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260034","volume":"16","author":"K Irak","year":"2021","unstructured":"Irak, K., M. Bayram, S. Cifci, and G. Sener. 2021. Serum levels of NLRC4 and MCP-2\/CCL8 in patients with active Crohn\u2019s disease. PLoS ONE 16 (11): e0260034. https:\/\/doi.org\/10.1371\/journal.pone.0260034.","journal-title":"PLoS ONE"},{"issue":"3","key":"1939_CR59","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/mi.2012.8","volume":"5","author":"FA Carvalho","year":"2012","unstructured":"Carvalho, F.A., I. Nalbantoglu, J.D. Aitken, R. Uchiyama, Y. Su, G.H. Doho, M. Vijay-Kumar, and A.T. Gewirtz. 2012. Cytosolic flagellin receptor NLRC4 protects mice against mucosal and systemic challenges. Mucosal Immunology 5 (3): 288\u2013298. https:\/\/doi.org\/10.1038\/mi.2012.8.","journal-title":"Mucosal Immunology"},{"key":"1939_CR60","doi-asserted-by":"publisher","first-page":"7256862","DOI":"10.1155\/2020\/7256862","volume":"2020","author":"Q Ge","year":"2020","unstructured":"Ge, Q., L. Zhao, C. Liu, X. Ren, Y.H. Yu, C. Pan, and Z. Hu. 2020. LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice.\u00a0BioMed Research International\u00a02020: 7256862. https:\/\/doi.org\/10.1155\/2020\/7256862.","journal-title":"Biomed Res Int"},{"key":"1939_CR61","doi-asserted-by":"publisher","first-page":"110824","DOI":"10.1016\/j.biopha.2020.110824","volume":"133","author":"Y Liu","year":"2021","unstructured":"Liu, Y., Y. Fan, J. Li, M. Chen, A. Chen, D. Yang, X. Guan, and Y. Cao. 2021. Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice. Biomed Pharmacother 133: 110824. https:\/\/doi.org\/10.1016\/j.biopha.2020.110824.","journal-title":"Biomed Pharmacother"},{"key":"1939_CR62","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/s1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon, F., K. Burns, and J. Tschopp. 2002. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Molecular Cell 10: 417\u2013426. https:\/\/doi.org\/10.1016\/s1097-2765(02)00599-3.","journal-title":"Molecular Cell"},{"key":"1939_CR63","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.coi.2019.04.015","volume":"60","author":"PS Mitchell","year":"2019","unstructured":"Mitchell, P.S., A. Sandstrom, and R.E. Vance. 2019. The NLRP1 inflammasome: New mechanistic insights and unresolved mysteries. Current Opinion in Immunology 60: 37\u201345. https:\/\/doi.org\/10.1016\/j.coi.2019.04.015.","journal-title":"Current Opinion in Immunology"},{"issue":"7237","key":"1939_CR64","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nature07725","volume":"458","author":"V Hornung","year":"2009","unstructured":"Hornung, V., A. Ablasser, M. Charrel-Dennis, F. Bauernfeind, G. Horvath, D.R. Caffrey, E. Latz, and K.A. Fitzgerald. 2009. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458 (7237): 514\u2013518. https:\/\/doi.org\/10.1038\/nature07725.","journal-title":"Nature"},{"issue":"7","key":"1939_CR65","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.4049\/jimmunol.2100449","volume":"207","author":"Y Hong","year":"2021","unstructured":"Hong, Y., S.O. Lee, C. Oh, K. Kang, J. Ryoo, D. Kim, and K. Ahn. 2021. USP21 Deubiquitinase Regulates AIM2 Inflammasome Activation. The Journal of Immunology 207 (7): 1926\u20131936. https:\/\/doi.org\/10.4049\/jimmunol.2100449.","journal-title":"The Journal of Immunology"},{"issue":"5","key":"1939_CR66","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.cell.2017.09.029","volume":"171","author":"EV Dang","year":"2017","unstructured":"Dang, E.V., J.G. McDonald, D.W. Russell, and J.G. Cyster. 2017. Oxysterol Restraint of Cholesterol Synthesis Prevents AIM2 Inflammasome Activation. Cell 171 (5): 1057-1071.e11. https:\/\/doi.org\/10.1016\/j.cell.2017.09.029.","journal-title":"Cell"},{"issue":"10","key":"1939_CR67","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201845737","volume":"19","author":"PH Wang","year":"2018","unstructured":"Wang, P.H., Z.W. Ye, J.J. Deng, K.L. Siu, W.W. Gao, V. Chaudhary, Y. Cheng, S.Y. Fung, K.S. Yuen, T.H. Ho, C.P. Chan, Y. Zhang, K.H. Kok, W. Yang, C.P. Chan, and D.Y. Jin. 2018. Inhibition of AIM2 inflammasome activation by a novel transcript isoform of IFI16. EMBO Reports 19 (10): e45737. https:\/\/doi.org\/10.15252\/embr.201845737.","journal-title":"EMBO Reports"},{"issue":"7366","key":"1939_CR68","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature10510","volume":"477","author":"Y Zhao","year":"2011","unstructured":"Zhao, Y., J. Yang, J. Shi, Y.N. Gong, Q. Lu, H. Xu, L. Liu, and F. Shao. 2011. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477 (7366): 596\u2013600. https:\/\/doi.org\/10.1038\/nature10510.","journal-title":"Nature"},{"issue":"4","key":"1939_CR69","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.cell.2018.02.055","volume":"173","author":"R Karki","year":"2018","unstructured":"Karki, R., E. Lee, D. Place, P. Samir, J. Mavuluri, B.R. Sharma, A. Balakrishnan, R.K.S. Malireddi, R. Geiger, Q. Zhu, G. Neale, and T.D. Kanneganti. 2018. IRF8 Regulates Transcription of Naips for NLRC4 Inflammasome Activation. Cell 173 (4): 920-933.e13. https:\/\/doi.org\/10.1016\/j.cell.2018.02.055.","journal-title":"Cell"},{"issue":"7421","key":"1939_CR70","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature11429","volume":"90","author":"Y Qu","year":"2012","unstructured":"Qu, Y., S. Misaghi, A. Izrael-Tomasevic, K. Newton, L.L. Gilmour, M. Lamkanfi, S. Louie, N. Kayagaki, J. Liu, L. K\u00f6m\u00fcves, J.E. Cupp, D. Arnott, D. Monack, and V.M. Dixit. 2012. Phosphorylation of NLRC4 is critical for inflammasome activation. Nature 90 (7421): 539\u2013542. https:\/\/doi.org\/10.1038\/nature11429.","journal-title":"Nature"},{"issue":"8","key":"1939_CR71","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.7150\/thno.55573","volume":"11","author":"C Guan","year":"2021","unstructured":"Guan, C., X. Huang, J. Yue, H. Xiang, S. Shaheen, Z. Jiang, Y. Tao, J. Tu, Z. Liu, Y. Yao, W. Yang, Z. Hou, J. Liu, X.D. Yang, Q. Zou, B. Su, Z. Liu, J. Ni, J. Cheng, and X. Wu. 2021. SIRT3-mediated deacetylation of NLRC4 promotes inflammasome activation. Theranostics 11 (8): 3981\u20133995. https:\/\/doi.org\/10.7150\/thno.55573.","journal-title":"Theranostics"},{"issue":"Pt A","key":"1939_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109379","volume":"113","author":"X Liu","year":"2022","unstructured":"Liu, X., D. Li, W. Pi, B. Wang, S. Xu, L. Yu, L. Yao, Z. Sun, J. Jiang, and Y. Mi. 2022. LCZ696 protects against doxorubicin-induced cardiotoxicity by inhibiting ferroptosis via AKT\/SIRT3\/SOD2 signaling pathway activation. International Immunopharmacology 113 (Pt A): 109379. https:\/\/doi.org\/10.1016\/j.intimp.2022.109379.","journal-title":"International Immunopharmacology"},{"key":"1939_CR73","doi-asserted-by":"publisher","first-page":"9815039","DOI":"10.1155\/2020\/9815039","volume":"2020","author":"S Peng","year":"2020","unstructured":"Peng, S., X.F. Lu, Y.D. Qi, J. Li, J. Xu, T.Y. Yuan, X.Y. Wu, Y. Ding, W.H. Li, G.Q. Zhou, Y. Wei, J. Li, S.W. Chen, and S.W. Liu. 2020. LCZ696 Ameliorates Oxidative Stress and Pressure Overload-Induced Pathological Cardiac Remodeling by Regulating the Sirt3\/MnSOD Pathway. Oxidative Medicine and Cellular Longevity 2020: 9815039. https:\/\/doi.org\/10.1155\/2020\/9815039.","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"1939_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100924","volume":"76","author":"KP Downs","year":"2020","unstructured":"Downs, K.P., H. Nguyen, A. Dorfleutner, and C. Stehlik. 2020. An overview of the non-canonical inflammasome. Molecular Aspects of Medicine 76: 100924. https:\/\/doi.org\/10.1016\/j.mam.2020.100924.","journal-title":"Molecular Aspects of Medicine"},{"issue":"2","key":"1939_CR75","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41418-020-00621-x","volume":"28","author":"A Poelzl","year":"2021","unstructured":"Poelzl, A., C. Lassnig, S. Tangermann, D. Hromadov\u00e1, U. Reichart, R. Gawish, K. Mueller, R. Moriggl, A. Linkermann, M. Gl\u00f6smann, L. Kenner, M. Mueller, and B. Strobl. 2021. TYK2 licenses non-canonical inflammasome activation during endotoxemia. Cell Death and Differentiation 28 (2): 748\u2013763. https:\/\/doi.org\/10.1038\/s41418-020-00621-x.","journal-title":"Cell Death and Differentiation"},{"issue":"5","key":"1939_CR76","doi-asserted-by":"publisher","first-page":"eaav5562","DOI":"10.1126\/sciadv.aav5562","volume":"5","author":"R Chen","year":"2019","unstructured":"Chen, R., L. Zeng, S. Zhu, J. Liu, H.J. Zeh, G. Kroemer, H. Wang, T.R. Billiar, J. Jiang, D. Tang, and R. Kang. 2019. cAMP metabolism controls caspase-11 inflammasome activation and pyroptosis in sepsis.\u00a0Science Advances\u00a05 (5): eaav5562. https:\/\/doi.org\/10.1126\/sciadv.aav5562.","journal-title":"Sci Adv"},{"issue":"7427","key":"1939_CR77","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature11588","volume":"492","author":"GS Lee","year":"2012","unstructured":"Lee, G.S., N. Subramanian, A.I. Kim, I. Aksentijevich, R. Goldbach-Mansky, D.B. Sacks, R.N. Germain, D.L. Kastner, and J.J. Chae. 2012. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 492 (7427): 123\u2013127. https:\/\/doi.org\/10.1038\/nature11588.","journal-title":"Nature"},{"issue":"4","key":"1939_CR78","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.immuni.2023.03.003","volume":"56","author":"F Zhu","year":"2023","unstructured":"Zhu, F., J. Ma, W. Li, Q. Liu, X. Qin, Y. Qian, C. Wang, Y. Zhang, Y. Li, D. Jiang, S. Wang, and P. Xia. 2023. The orphan receptor Nur77 binds cytoplasmic LPS to activate the non-canonical NLRP3 inflammasome. Immunity 56 (4): 753-767.e8. https:\/\/doi.org\/10.1016\/j.immuni.2023.03.003.","journal-title":"Immunity"},{"key":"1939_CR79","doi-asserted-by":"publisher","first-page":"845185","DOI":"10.3389\/fphar.2022.845185","volume":"13","author":"T Liang","year":"2022","unstructured":"Liang, T., Y. Zhang, S. Wu, Q. Chen, and L. Wang. 2022. The Role of NLRP3 Inflammasome in Alzheimer\u2019s Disease and Potential Therapeutic Targets.\u00a0Frontiers in\u00a0Pharmacology\u00a013: 845185. https:\/\/doi.org\/10.3389\/fphar.2022.845185.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1939_CR80","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2174\/156720508783954703","volume":"5","author":"LB Hersh","year":"2008","unstructured":"Hersh, L.B., and D.W. Rodgers. 2008. Neprilysin and amyloid beta peptide degradation.\u00a0Current Alzheimer Research\u00a05 (2): 225\u2013231. https:\/\/doi.org\/10.2174\/156720508783954703.","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"1939_CR81","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40256-020-00445-7","volume":"21","author":"J Galo","year":"2021","unstructured":"Galo, J., D. Celli, and R. Colombo. 2021. Effect of Sacubitril\/Valsartan on Neurocognitive Function: Current Status and Future Directions.\u00a0American Journal\u00a0of\u00a0Cardiovascular Drugs\u00a021 (3): 267\u2013270. https:\/\/doi.org\/10.1007\/s40256-020-00445-7.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1939_CR82","doi-asserted-by":"publisher","unstructured":"Li, B.,\u00a0Y. Zhao,  B. Yin,  M. Helian,  X. Wang,  F. Chen,  H. Zhang,  H. Sun, B. Meng, and F. An. 2017. Safety of the neprilysin\/renin-angiotensin system inhibitor LCZ696. Oncotarget 8 (47): 83323\u201383333. https:\/\/doi.org\/10.18632\/oncotarget.18312.","DOI":"10.18632\/oncotarget.18312"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-023-01939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10753-023-01939-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-023-01939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T08:09:49Z","timestamp":1714982989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10753-023-01939-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1939"],"URL":"https:\/\/doi.org\/10.1007\/s10753-023-01939-7","relation":{},"ISSN":["0360-3997","1573-2576"],"issn-type":[{"value":"0360-3997","type":"print"},{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"14 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"During the preparation of this work the author(s) used ChatGPT in order to improve language. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Generative AI and AI-assisted Technologies in the Writing Process"}}]}}